

//
//

()

MIC (ESBLs)

*

MIC

MIC

MIC

MIC ESBLs

CLSI

ESBLs

$\mu\text{m/ml}$

$\mu\text{m/ml}$

MIC

MIC

ESBL

(n=)

/ ESBLs

ESBLs

(n=) /

(n=) /

MIC

MIC

MIC

/

ESBLs

:

ESBLs

ESBLs

ESBLs :

CLSI

ESBLs

(ESBL)

.()

ESBLs.()

()

.()

ESBLs

.()

ESBLs

ESBL

MIC

MIC

ESBL


.()

.()


ESBLs

ESBLs

(n=)




()




()


(n=)
 MIC /
 (P⁺C⁻) (n=)
 ESBL ESBL
 ESBL *E.coli*
 (/) / ESBL
E.coli (n=)
 / (P⁺C⁺)



ESBL
 ()



ESBL
 ()



ESBL

(ESBLs)

ESBL

() ESBL

ESBL ()

() ESBL

ESBL

()

/

(ESBLs)

()

ESBL

()

ESBL

()

(n=) / ESBLs

ESBL

/

CT E-Test DDT
 DDT
 E-Test % / CT % /
 % / ESBLs % / ESBL
 .()

MICs (n=) / (P+C)
 MIC %
 mcg/ml MIC AmpC
 mcg/ml
 MIC AmpC .()
 % %
 mcg/ml MIC
 mcg/ml () α
 ESBL
) ESBL
 .()
 (Breakpoint)

ESBL
 ESBL
 ESBLs
 MIC .() ESBLs
 % / MIC
 ESBL
 MIC ≥ mcg/ml .() MIC ≥ %
 ≥ mcg/ml ESBLs

MIC ESBL
mcg/ml

(CLSI)

. () MIC
≥ mcg/ml ≥ mcg/ml

(CLSI)
MIC ≤ mcg/ml

ESBLs

ESBLs

ESBLs

μg/ml MIC ESBL
MIC %
≤ mcg/ml
. ()
% %
MIC

ESBLs

REFERENCES

1. Raul C. Extended-spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists. *Am J Infect Control* 2005; 33: 104-7.
2. Konthe H, Shah P, Krcmery V, Antal M, Mitsuhasi S. Transferable resistance to Cefotaxime, Cefoxitin, Cefamandole and Cefuroxime in clinical isolates of *Klebsiella pneumoniae* and

- Cefuroxim in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection* 1983; 11: 315-17.
3. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. *Antimicrob Agents Chemother* 1989; 33: 1131-6.
 4. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *Clin Infect Dis* 2001; 32: 1162-71.
 5. Blondeau JM. Extended-spectrum beta-lactamases. *Semin Respir Infect* 2001; 16: 169-76.
 6. Clinical and laboratory standards Institute: Performance Standards for Antimicrobial Susceptibility testing: Fifteenth Informational supplement 2005; 25(1): 100-15.
 7. Queenan AM, Foleno B, Gownloy C. Effect of inoculum and β -lactamase activity in AmpC and Extended-spectrum β -lactamases(ESBLs)-producing *Escherichia coli* and *Klebsiella pneumoniae* clinical isolates tested by NCCLS ESBL methodology. *J Clin Microbiol* 2004; 42(1): 269-75.
 8. Pterson DL, Bonomo RA. Extended-spectrum β -lactamases: a clinical update. *Clin Microbiol Rev* 2005; 18 (4):657-86.
 9. Stobberingh EE, Arends J, Hoogkamp-Korstanje JA, Goessens WH, Visser MR, Buiting AG, et al. Occurrence of extended-spectrum beta-lactamases in Dutch hospitals. *Infection* 1999; 27: 348-54.
 10. Branger C, Lesimple AL, Bruneu B, Berry, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of *Klebsiella pneumoniae* isolates producing extended-spectrum beta-lactamases in a university hospital. *J Med Microbiol* 1998; 47: 209-10.
 11. Bradford PA. Extended-spectrum β -lactamases in the 21st century: characterisation, epidemiology and detection of this important resistance threat. *Clin Microbiol Rev* 2001; 14 (4): 933-51.
 12. Yagi T, Kruokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum β -lactamases in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli* in Japan. *FEMS Microbiol Lett* 2000; 184: 53-6.
 13. European Antimicrobial Resistance Surveillance System Annual Report 2005, On-going surveillance of *S.pneumoniae*, *S. aureus*, *E. coli*, *E. faecalis*, *K. pneumoniae* and *P. aeruginosa*, EARSS, Bilthoven, The Netherlands, October 2006.
 14. Shah AA, Hasan F, Ahmad S, Hameed A. Characteristic epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β -lactamases. *Research in Microbiology* 2004; 155: 409-21.
 15. Philipon A, Arlet G, Jacoby AG. Plasmid-determined AmpC-Type β -lactamases. *Antimicrob Agents Chemother* 2002; 46(1): 1-11.
 16. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, Jones RN. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of *Escherichia coli* and *Klebsiella pneumoniae*: results from the SENTRY Asia-Pacific Surveillance Program. *J Clin Microbiol* 2007; 45(5): 1478-82.

MIC ESBLs

18. Mobaiyen H, Nahaei MR, Amirmizafari N, Moaddab SR, Hoseni F. First report of CTX-M type β -lactamases-production in clinical *Escherichia coli* isolates from intensive care units in Tabriz. 1st Iranian Congress of Clinical Microbiology. Shiraz 2007; P: 66.
19. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.